贝伐珠单抗治疗早产儿视网膜病变后的神经发育结局:一项Meta分析
该Meta分析纳入8项比较研究,评估早产儿视网膜病变(ROP)患儿接受玻璃体腔注射贝伐珠单抗(IVB)后的神经发育结局。结果显示IVB组严重神经发育障碍(sNDI)风险未增加(OR 1.39,95%CI 0.98-1.97),Bayley III认知和语言评分无显著差异,仅运动评分有轻微差异(MD -3.66,95%CI -6.79至-0.54),脑性瘫痪风险无差异。证据质量低至极低,需随机试验验证。
要点
- IVB治疗后ROP患儿sNDI风险未显著增加(OR 1.39,95%CI 0.98-1.97)。
- Bayley III运动评分IVB组略低(MD -3.66,95%CI -6.79至-0.54),认知和语言无差异。
- 脑性瘫痪风险无差异(OR 1.20,95%CI 0.56-2.55),证据质量低至极低。
核心结论
- ROP患儿接受IVB治疗后严重神经发育障碍风险未增加。
- Bayley III认知和语言评分与对照组相似,仅运动表现有轻微差异。
研究设计与样本
- Meta分析检索PubMed、Embase和Web of Science从建库至2020年3月12日的文献。
- 纳入8项比较研究,其中6项对照为激光治疗的ROP患儿,2项对照为无需治疗的ROP患儿。
主要发现
- sNDI的加权OR为1.39(95%CI 0.98-1.97)。
- Bayley III认知、语言和运动评分的加权MD分别为-1.92(95%CI -4.73至0.88)、-1.32(95%CI -4.65至1.99)和-3.66(95%CI -6.79至-0.54)。
- 脑性瘫痪的OR为1.20(95%CI 0.56-2.55)。
- 预设亚组(激光对照ROP患儿与无需治疗ROP患儿)间无差异。
关键数值与推荐
- 主要结局为sNDI,计算OR;次要结局为Bayley III认知、语言、运动评分MD及脑性瘫痪OR。
- 证据质量评级:sNDI和所有Bayley III评分为低,脑性瘫痪为极低。
临床怎么用
- IVB治疗ROP后额外严重神经发育障碍风险较低,但运动评分轻微差异需关注。
- 当前证据质量低,临床决策应结合个体情况并期待随机试验提供更高证据。
局限性
- 纳入研究数量有限(8项),证据质量低至极低。
- 缺乏随机对照试验,需随机试验提供更高等级证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate neurodevelopmental outcomes after intravitreal bevacizumab (IVB) therapy in retinopathy of prematurity (ROP) infants compared with those not exposed to IVB. CLINICAL RELEVANCE: The primary concern regarding IVB treatment of ROP is the potential systemic side effects, especially the risk of causing severe neurodevelopmental impairment (sNDI). Results regarding neurodevelopmental outcomes after IVB therapy are conflicting. METHODS: We conducted a meta-analysis and searched PubMed, Embase, and Web of Science for related publications from inception through March 12, 2020. The eligibility criteria were as follows: comparative studies of ROP patients that (1) included IVB as a treatment arm, (2) included a control group without bevacizumab treatment, and (3) reported on at least 1 neurodevelopmental outcome, such as sNDI, Bayley Scales of Infant and Toddler Development, Third Edition (Bayley III), composition scores, or cerebral palsy (CP). The primary outcome was sNDI, with the odds ratio (OR) calculated. Secondary outcomes were mean differences (MDs) for cognitive, language, and motor scores (Bayley III) and OR for CP. The quality of evidence was assessed using the Grades of Recommendation, Assessment, Development, and Evaluation approach. RESULTS: Eight studies, 6 including laser-controlled ROP infants and 2 including ROP infants not requiring treatment, were included. The weighted OR for sNDI in the IVB group was 1.39 (95% confidence interval [CI], 0.98-1.97). The weighted MDs were -1.92 (95% CI, -4.73 to 0.88), -1.32 (95% CI, -4.65 to 1.99), and -3.66 (95% CI, -6.79 to -0.54) for cognitive, language, and motor scores in Bayley III, respectively. The OR for CP was 1.20 (95% CI, 0.56-2.55). No differences were observed between the preset subgroups comprising laser-controlled ROP infants and ROP infants not requiring treatment. The current quality of evidence was rated as low (sNDI and all Bayley III scores) to very low (CP). CONCLUSIONS: Risk of sNDI was not increased in ROP patients after IVB treatment. Bayley III scores were similar in the IVB and control groups, except for a minor difference in motor performance. These findings suggest that the risk of additional sNDI after IVB treatment is low. Randomized trials are warranted to provide a higher quality of evidence.
引用
- Tsai CY, Yeh PT, Tsao PN, et al. Neurodevelopmental Outcomes after Bevacizumab Treatment for Retinopathy of Prematurity: A Meta-analysis. Ophthalmology. 2020. PMID: 33212122. doi:10.1016/j.ophtha.2020.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。